A handful of unexpected knockbacks by the FDA this year had biopharma followers wondering whether the US regulator had sharpened its teeth. The raw numbers do not seem to support this idea, with 45 novel agents having received a green light so far in 2020, only four fewer than last year’s total.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,